LENSAR, Inc.

NasdaqCM LNSR

LENSAR, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -19.59%

LENSAR, Inc. EBIT Margin is -19.59% for the Trailing 12 Months (TTM) ending September 30, 2024, a 35.72% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

LENSAR, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -30.47%, a 49.32% change year over year.
LENSAR, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -60.13%, a 15.96% change year over year.
LENSAR, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -71.55%, a -41.64% change year over year.
LENSAR, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -50.52%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: LNSR

LENSAR, Inc.

CEO	Mr. Nicholas T. Curtis
IPO Date	Oct. 2, 2020
Location	United States
Headquarters	2800 Discovery Drive
Employees	130
Sector	Consumer Discretionary
Industries Eyewear Augmented Reality (AR) Cosmetics

Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

Key trends

Past 5 years